Stay updated on PK Interaction Study Sitravatinib P-gp Modulators Clinical Trial
Sign up to get notified when there's something new on the PK Interaction Study Sitravatinib P-gp Modulators Clinical Trial page.

Latest updates to the PK Interaction Study Sitravatinib P-gp Modulators Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a dedicated Locations section showing Dallas, Texas as a study site. The footer entries for HHS Vulnerability Disclosure and Texas Locations were removed, and the page revision is now v3.3.3.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedRevision: v3.3.2 updated on the page, replacing v3.2.0. No study content or functionality appears to be affected.SummaryDifference0.1%

- Check50 days agoChange DetectedRemoved the notice about potential delays and government operating status; the banner regarding funding updates no longer appears. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check71 days agoChange DetectedMinor layout and formatting updates are visible. Core content such as eligibility criteria, study plan, and outcome measures remains unchanged.SummaryDifference0.4%

- Check93 days agoChange DetectedNew operating-status notice and version update to v3.2.0; previous v3.1.0 version tag removed.SummaryDifference4%

- Check100 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to PK Interaction Study Sitravatinib P-gp Modulators Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PK Interaction Study Sitravatinib P-gp Modulators Clinical Trial page.